Our vision is to deliver disease-modifying therapies for CMT1A and related rare neurological disorders.

 ​​

The Challenge

Patients with CMT1A and related inherited peripheral neuropathies still have no approved disease-modifying treatment options. A better path forward requires a more predictive, biologically grounded approach to drug discovery.

​

​How We Aim to Change It

CELLTIUM is building a precision neurotherapeutics company that integrates disease biology, quantitative phenotyping, and AI/ML-driven analytics from the earliest stages of discovery. We translate complex neurobiology into differentiated medicines with the potential for meaningful clinical impact.

​

​Our Approach

Our work is grounded in predictive cellular and in vivo models designed to capture the core biology of rare neurological disorders. Built on this foundation, the proprietary PRECISION™ platform accelerates target discovery, candidate prioritization, and lead optimization.

​

​Our Commitment

CELLTIUM holds its science to the highest standards, with the rigor and urgency patients and families deserve.

​